RxDoctor Payments Data

Casey Wineland

Family · Bellefonte, PANPI 1780337485

Payments from drug & device makers

$1,887in general payments, 2019–2025

Across 83 payments — averaging $22.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$393
  • GSK$334
  • Novo Nordisk$225
  • Lilly USA, LLC$223
  • Pfizer$195
  • AstraZeneca$94
  • plus $423 from 8 others

What the payments were for

  • Food & beverage$1,887100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,887 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$14,022
Medicare patients
83
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$25,075
JardianceEmpagliflozin23$24,735
EliquisApixaban26$24,180
JanuviaSitagliptin Phosphate12$6,420
TradjentaLinagliptin11$5,684
Atorvastatin Calcium95$1,397
Telmisartan36$1,032
Esomeprazole Magnesium27$910
Pantoprazole Sodium50$871
Levothyroxine Sodium71$719
Rosuvastatin Calcium71$597
Olmesartan Medoxomil15$589
Losartan Potassium46$571
Metoprolol Succinate28$530
Montelukast Sodium24$517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$225$25,07519 claims
PfizerEliquis$195$24,18026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.

Other family in Bellefonte

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →